Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a fully human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis ...Wikipedia
Manufacturer's Website: Arzerra Average retail cost: $580/vial
Search Terms: Arzerra, ofatumumab, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis, relapsing remitting multiple sclerosis